Risperidone use at a state hospital: A clinical audit 2 years after the first wave of risperidone prescriptions

Journal of Clinical Psychiatry

Volumn 60, Issue 6, 1999, Pages 373-378

  Chengappa, K N Roy ^a,d   Sheth, Sapna ^e   Brar, Jaspreet S ^e   Parepally, Haranath ^a   Marcus, Steve ^e   Gopalani, Aziz ^a   Palmer, Antony ^a   Baker, Robert W ^a,b   Schooler, Nina R ^c  

^a Mayview State Hospital   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; BENZATROPINE MESILATE; CLOZAPINE; DIPHENHYDRAMINE; DROPERIDOL; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; RISPERIDONE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; DOSE CALCULATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0032997288     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0605     Document Type: Article

References (6)

1. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-35
2. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
3. Negron AE, Leiderman EA, Parkadavil M, et al. A naturalistic outcome study of risperidone treatment among state hospital patients. Psychiatr Serv 1996;47:1118-1120
4. Albright PS, Livingstone S, Keegan DL. et al. Reduction of healthcare resource utilization and costs following the use of risperidone for patients with schizophrenia previously treated with antipsychotic therapy. Clin Drug Invest 1996;11:289-299
5. Guest JF, Hart WM, Cookson RF, et al. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Econ 1996;10:59-67
6. Finley PR, Sommer BR, Corbitt JL, et al. Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol Bull 1998;34:75-81